In a recent Restaurant Dive article, William Blair’s consumer engagement survey, led by research analyst Dylan Carden, was cited as background on customer participation in restaurant loyalty programs.

Equity Research
In a recent Restaurant Dive article, William Blair’s consumer engagement survey, led by research analyst Dylan Carden, was cited as background on customer participation in restaurant loyalty programs.
Stay up-to-date with the latest William Blair news and insights
William Blair initiated research coverage of Zentalis Pharmaceuticals, Inc. (ZNTL $3.50), a clinical-stage biotech company focused on developing azenosertib, a small-molecule WEE1 inhibitor, for the treatment of ovarian cancer and other tumors.
Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.
For disclosure information, please visit www.williamblair.com/disclosures